US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Ambrx Biopharma Inc (AMAM)
Ambrx Biopharma Inc (AMAM) ニュース

AMAM

Ambrx Biopharma (AMAM)

Ambrx Biopharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AMAM

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/03/19	03 : 45	Edgar (US Regulatory)	Form 15-12G - Securities registration termination [Section 12(g)]	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/13	05 : 55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/11	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/09	03 : 39	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/09	03 : 34	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/09	03 : 29	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/09	03 : 24	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/09	03 : 20	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/08	03 : 23	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/07	22 : 49	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/03/07	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/02/24	04 : 09	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/02/22	22 : 31	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/02/22	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/02/13	03 : 43	PR Newswire (US)	Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/01/11	05 : 07	PR Newswire (US)	Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law Firm	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/01/09	04 : 54	Dow Jones News	Trending: Johnson & Johnson and Merck & Co. Announce Acquisitions	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/01/09	00 : 04	Dow Jones News	Ambrx Biopharma Shares Double on $2 Billion Acquisition by Johnson & Johnson	NASDAQ:AMAM	Ambrx Biopharma Inc
2024/01/08	22 : 12	Dow Jones News	Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2 Billion	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/10/24	06 : 19	Edgar (US Regulatory)	Form 15-12G - Securities registration termination [Section 12(g)]	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/09/16	05 : 27	Edgar (US Regulatory)	Form DEFM14A - Definitive proxy statement relating to merger or acquisition	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/09/16	05 : 24	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/09/07	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/08/26	06 : 23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/07/19	22 : 49	Dow Jones News	Ambrx Biopharma Gets Fast Track Designation for ARX517 Cancer Treatment	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/06/29	05 : 46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/06/29	05 : 45	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/06/29	05 : 07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/06/29	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AMAM	Ambrx Biopharma Inc
2023/06/10	05 : 12	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:AMAM	Ambrx Biopharma Inc

Showing the most relevant articles for your search:NASDAQ:AMAM

Verizon Communications

US Dollar vs Yen

JP Morgan Chase

Invesco QQQ Trust Series 1

Energy Select Sector SPDR

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約